Call for more medical access to commonly used illicit drugs
Prescription psilocybin, the hallucinogenic compound found in magic mushrooms, will become available to treat prescription-resistant depression.
Photo:
Pixabay
The Drug Foundation wants more medical access to some of the most commonly used illicit drugs.
It comes after the government
announced prescription psilocybin
, the hallucinogenic compound found in magic mushrooms, will become available to treat prescription-resistant depression.
The Drug Foundation's annual report found psychedelic drug use has more than doubled in New Zealand, with 3.1 percent of adults reported taking psychedelics like LSD, psilocybin and ketamine in 2023 and 2024, compared to 1.3 percent in 2017 and 2018.
It said cannabis, MDMA, and psychedelics rank down the lower end of the potential harm spectrum, and have well-documented medical uses.
The Drug Foundation's executive director Sarah Helm said some people are self-medicating with such drugs, and are being criminalised by not being allowed to access them legally.
"Many of our most popular illicit substances have well-documented medicinal uses and are being actively studied for their potential to treat a range of health conditions, so it's likely at least some of the use in this report is self-medication," Helm said.
"We think it's time to enable more medical access to the likes of psychedelics and MDMA and stop prosecuting people who use them."
In Australia, MDMA, known as ecstasy in tablet form, is being used to help treat
post-traumatic stress disorder
(PTSD).
While earlier this year, a clinical study using mushrooms containing psilocybin to
treat methamphetamine addiction
completed its first phase of trials.
"Criminalising anyone doesn't really help, whether the substance use is problematic or therapeutic," Helm told
Morning Report. "
Certainly, they [psychedelics] have been stigmatised and that's prevented access."
NZ Drug Foundation executive director Sarah Helm.
Photo:
Supplied/ NZ Drug Foundation
The release of these numbers coincides with Associate Health Minister David Seymour's announcement that psilocybin would be legally available in New Zealand outside of trials for the first time.
It brings New Zealand in line with Australia, which has been using psilocybin to treat depression
since 2023
.
Seymour said it would initially only be available from one specific psychiatrist, but he hoped more would apply.
The psychiatrist, Ōtautahi -based Dr Cameron Lacey, who was also behind the first clinical trials of psilocybin, said about two thirds of people who participated in clinical trials saw substantial improvements in their depression.
"It's truly providing remarkable results and it's really exciting to see a treatment that is providing real benefit for people who typically, at that point in their treatment journey, had a really long road and low improvement from standard treatments," Dr Lacey told
Morning Report.
Dr Cameron Lacey.
Photo:
Supplied
The therapy involves months of psychotherapy and one or two eight-hour psilocybin sessions or 'doses' accompanied by clinical professionals. Most of the studies have involved one or two doses integrated with a course of psychotherapy. For some, just
one treatment can be sufficient
.
"The most important thing that we need to work on next is making sure this treatment is available to all who need it," Dr Lacy said.
Helm said the announcement that the magic mushroom drug psilocybin will be available for some patients is good news, but better access is needed.
"We do need to see a broader range of clinicians making it available, otherwise people do turn to self-administration. It's happens in the cannabis field, as well. It is about balancing," Helm said.
Sign up for Ngā Pitopito Kōrero
,
a daily newsletter curated by our editors and delivered straight to your inbox every weekday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RNZ News
an hour ago
- RNZ News
Overstimulation is a normal human response. Here's how to cope with it
By Kellie Scott , ABC Photo: 123rf It's 5pm. The dog is barking. The kids are screaming. The TV is blaring. And the oven is beeping. This is peak overstimulation for Meghan Flood. The 29-year-old from Blackwater/Gangulu Country in Central Queensland is a stay-at-home mum to children aged two and four. Her husband works long hours, and they have no family support, with their loved ones back in Tasmania/Lutruwita. "I struggle daily," says Meghan. Overstimulation, also called sensory overload, is when the brain receives sensory input at an intensity or duration that exceeds an individual's capacity to effectively process it, says Sara Quinn. She's a clinical psychologist and president of the Australian Psychological Society. It's not a diagnosable condition, Dr Quinn says, but an experience that is "very much dictated by a person's capacity". "What might be seemingly manageable for one person, or even positively stimulating for one person, may for another be an experience that is quite overwhelming or overloading and stressful." She says overstimulation is likely on the rise in modern life. "We're living in an increasingly technology driven world, with less time spent outdoors in environments that might be restorative." Meghan Flood says parenting two small children at home with a dog can be very overstimulating. (Supplied) Photo: Meghan Flood / Supplied Sensory overload reflects a mismatch between what the environment demands of somebody and their capacity to process it, says Dr Quinn. It can be related to light, sound, taste, touch, and smell. Dr Quinn says what causes overstimulation is highly subjective, but more typical triggers include loud sounds like music or fireworks, busy crowds, or strong smells. "For others, especially in children, we see the sensation of a particular type of stimuli on skin like scratchy material. Family coach Hélène Gatland says people may also experience overstimulation when there are too many demands at once, such as chores, work and "kids asking questions", or a cluttered or chaotic environment. Dr Quinn says things may lead to feeling teary, distressed, stressed, anxious and confused. "Other people might experience irritability, agitation and even anger." As people attempt to escape or mitigate overstimulation, their emotional state may change. "For children, it might manifest as a tantrum, meltdown, or withdrawal or anxiety in adults," Dr Quinn says. There can be physical signs, too, such as headaches, muscle tension, or fatigue, says Ms Gatland. Anyone can experience sensory overload, and what we can tolerate may differ from time to time depending on a range of factors, explains Dr Quinn. For example, when someone is fatigued or stressed. It can also be associated with mental health conditions, and neurodivergence such as autism and ADHD, says Dr Quinn. "Someone with anxiety might have heightened sensitivity … as we know for people with neurodivergence there can be difficulty filtering sensory input, which might lead to being more easily overstimulated. "We know that individuals who are in throws of dementia, actually experience impaired sensory integration." Meghan says sensitivity to overstimulation has increased with each child she's had. Ms Gatland says parenting young children can be a really demanding, noisy time of life. "You only stop when you sleep, if you can go to sleep. "It's a 24-hour job … and if you don't have time to rest, it gets much harder." People in high-pressure jobs might find sensory overload common, she says. "If you have to do lots of decision-making at the same time, or you have a meeting and someone is calling you and someone else is asking you a question - that can be very overstimulating." Noise-cancelling headphones can also be helpful for people triggered by noise. Photo: Getty Images Meghan says her strategy for dealing with sensory overload is locking herself in the bedroom. "But it's just a band-aid," she says. Ms Gatland says taking micro-breaks, even pockets of five minutes, can help people experiencing overstimulation. "Step outside, sit in the car for a minute alone. "If you can take five minutes just to tap into your nervous system, using techniques like breathing or massaging yourself, that will help calm you." Noise-cancelling headphones can also be helpful for people triggered by noise, she says. Earplugs may suffice. "It's about lowering your sensory input - turning off the TV when no-one is watching and it's not helping the household." Tidying up cluttered spaces, whether at work or in the home, may also help, as well as dimming lighting, and creating "nice" spaces to be in. Dr Quinn says creating visual "quiet" can be as important as adjusting sound. She recommends reducing our digital exposure, by putting our phone on do not disturb and turning off app notifications when suitable. And spending time in nature will help improve intentional restoration, Dr Quinn says. "Taking off your shoes, walking barefoot on the grass. Taking a walk around your back garden. Even small things, like having plants around your workspace." For parents who can't be alone in that moment, take the kids outside with you, she suggests. Ms Gatland encourages people to communicate what they need to those around them, whether it's their kid, partner, or colleagues, for example. She says it's helpful to remember overstimulation is a normal human response. "It's not a failure, it's your body telling you to pause and recharge, not push through." Those who need more support should talk to their GP or reach out to a psychologist, says Dr Quinn. "Primarily we want to shift them from a sense of loss of control towards greater psychological flexibility … and give them strategies to manage stress." - ABC
RNZ News
2 hours ago
- RNZ News
Private hospitals' use of publicly-funded cancer drugs will widen inequities, warn doctors
Under 'transitional access' private patients won't have to shift to the public system for 12 months. Photo: 123RF A move to allow private patients to access publicly-funded cancer drugs threatens to increase wait times for those in the public system, warn senior doctors. Under "transitional access", which comes into effect on 1 July, private patients who are already receiving treatment - or about to start treatment - with a newly funded medicine will not have to shift to the public system for 12 months. Associate Health Minister David Seymour, who has championed the rule change, said it would lessen stress on private patients by enabling continuity of care, and pressure on the public system which would no longer have to deal with a sudden influx of patients. However, the move has been criticised by opposition politicians as "a subsidy for private insurers", which already cover the cost of medicines newly funded by Pharmac, and of little benefit to patients. The Association of Salaried Medical Specialists, which represents 6500 senior hospital doctors and dentists, said its members working in oncology and haematology had "significant concerns" the change would widen inequities for patients. In a letter on June 13 to Pharmac's acting chief executive Brendan Boyle, the union's director of policy and research, Harriet Wild, quoted a briefing to the minister saying the policy change "would not increase volumes of cancer medicines provided in New Zealand, as only the location of treatments will change". "It will simply shift some of the existing capacity to the private system, where patients will need to fund infusion costs out-of-pocket," Wild wrote. "There will be pressure on the public system to ensure a smooth transition in treatment regime, which may mean delaying treatment for other people already waiting on the public list and unable to self-fund to start in private. "This potentially creates a two-tier waiting list and a system where those with more financial resources, will be prioritised for treatment." Furthermore, the shift of resources and inevitable increase in demand was likely to speed up the exodus of staff to the private sector, making public waiting lists even longer. A "back-pocket Q&A" provided to Seymour ahead of a Cabinet meeting on April 7 noted that the current eligibility criteria in the Pharmaceutical Schedule (excluding patients in private settings) was "designed to ensure public funding for medicines was prioritised for those managed in the public health system for cancer treatment, assessed by need, rather than public funding supporting those who chose to access treatment in private facilities. "Often the private treatment is funded from private health insurance that people have paid premiums into." In the same document, the minister said there was no plan to expand the policy to include other types of medicines or treatments "at this stage". "With that said, I've asked the Ministry [of Health] to do further work in this area to explore the possibility of broadening access to all publicly-funded medicines in private facilities - not just newly funded cancer medicines. "I encourage the private health providers and insurance companies to work closely with the ministry to support their understanding of how this might work in practice." Wild said opening access to publicly-funded drugs even wider would pull more staff away from the public system, reducing access for the majority who relied on it. "That would establish a system where a patient's ability to receive timely cancer care would depend on whether they could afford the out-of-pocket infusion costs." The government's 2024 Budget boost to Pharmac to widen access to medicines for patients had not been accompanied by extra resources for Te Whatu Ora to deliver the treatments, when public oncology services were already swamped with demand, Wild said. "Our members are increasingly needing to manage deteriorating patients, who are unable to access chemotherapy infusions in clinically acceptable timeframes. "This is unacceptable and represents a significant failure to invest in a planned and co-ordinated way to enable the public system to meet the needs of cancer patients, including those eligible for newly funded cancer medicines. "Whenever a new cancer drug is funded, it must be accompanied by an increase in the full package of care (staffing, infusion space, pharmacy) so that patients can actually receive the medicines within clinically acceptable timeframes." The Health Minister and David Seymour's office have been approached for comment. Sign up for Ngā Pitopito Kōrero , a daily newsletter curated by our editors and delivered straight to your inbox every weekday.
RNZ News
5 hours ago
- RNZ News
Psilocybin approved for depression
The government has announced the 'magic mushroom' drug psilocybin will become available for patients with treatment-resistant depression. Psychiatrist, Cameron Lacey, spoke to Ingrid Hipkiss. Tags: To embed this content on your own webpage, cut and paste the following: See terms of use.
